Holen Sie sich die Stockscreener-App
8.49
1.62%
-0.14
Handel nachbörslich:
8.46
-0.03
-0.35%
Zevra Therapeutics Inc Aktie (ZVRA) Neueste Nachrichten
Can Zevra Therapeutics Inc. stock withstand economic slowdownJuly 2025 Sentiment & Verified Entry Point Signals - ulpravda.ru
Can Zevra Therapeutics Inc. stock double in next 5 yearsJuly 2025 Gainers & Reliable Volume Spike Alerts - ulpravda.ru
Is Zevra Therapeutics Inc. stock a top pick in earnings season2025 Risk Factors & Fast Gain Swing Alerts - ulpravda.ru
What Wall Street predicts for Zevra Therapeutics Inc. stock priceAnalyst Downgrade & Precise Entry and Exit Recommendations - ulpravda.ru
How Zevra Therapeutics Inc. stock benefits from tech adoptionEarnings Risk Summary & Weekly High Potential Alerts - ulpravda.ru
Will Zevra Therapeutics Inc. stock deliver strong dividend growthJuly 2025 Reactions & Consistent Growth Equity Picks - ulpravda.ru
Is Zevra Therapeutics Inc. stock a buy before product launchesWeekly Gains Summary & Weekly Stock Performance Updates - ulpravda.ru
Can Zevra Therapeutics Inc. stock sustain revenue growth2025 Market WrapUp & Intraday High Probability Alerts - ulpravda.ru
Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference - The Manila Times
Zevra Therapeutics to Present at J.P. Morgan 44th Annual Healthcare Conference on January 15, 2026 - Quiver Quantitative
Precision Trading with Zevra Therapeutics Inc. (ZVRA) Risk Zones - Stock Traders Daily
Sell Signal: How Zevra Therapeutics Inc stock benefits from tech adoptionLayoff News & Free Real-Time Volume Trigger Notifications - moha.gov.vn
Is Zevra Therapeutics (ZVRA) Using Expanded Access To Quietly Recast Its Rare-Disease Growth Story? - Sahm
TheStreet - thestreet.com
Zevra Therapeutics: Asymmetric Risk-Reward Setup In Ultra-Rare Disease Market - Seeking Alpha
Analysts’ Top Healthcare Picks: Ultragenyx Pharmaceutical (RARE), Zevra Therapeutics (ZVRA) - The Globe and Mail
Zevra Therapeutics announces CFO transition - MSN
Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO) and Zevra Therapeutics (ZVRA) - The Globe and Mail
Zevra Therapeutics stock maintains Buy rating at H.C. Wainwright on expanded access deal - Investing.com Nigeria
ZVRA Boosts Distribution for Miplyffa with Uniphar Agreement - GuruFocus
Zevra Therapeutics executes distribution agreement to broaden access to Miplyffa for the treatment of Niemann-Pick disease type C (NPC) - marketscreener.com
Zevra Therapeutics Signs Expanded Miplyffa Distribution Deal With Uniphar - marketscreener.com
Zevra Therapeutics (ZVRA) Expands MIPLYFFA Access with Uniphar A - GuruFocus
Zevra Therapeutics Signs Expanded Access Agreement with Uniphar to Enhance Availability of MIPLYFFA® for Niemann-Pick Disease Type C Patients - Quiver Quantitative
Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C (NPC) - The Manila Times
New deal expands access to a vital Niemann-Pick C treatment beyond Europe - Stock Titan
How Zevra Therapeutics Inc. (ZVRA) Affects Rotational Strategy Timing - Stock Traders Daily
Can Zevra Therapeutics Stock Hold Up When Markets Turn? - Trefis
Profit Review: How institutional buying supports Zevra Therapeutics Inc. stockJuly 2025 Trends & Long-Term Growth Stock Strategies - Улправда
Analysts’ Top Healthcare Picks: Zevra Therapeutics (ZVRA), Novan (NOVN) - The Globe and Mail
Discipline and Rules-Based Execution in ZVRA Response - Stock Traders Daily
Is Zevra Therapeutics Attractively Priced After Recent Rare Disease Pipeline Progress? - Yahoo Finance
Is Zevra Therapeutics (ZVRA) Undervalued After Its Recent Share Price Pullback? - Yahoo Finance
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Zevra Therapeutics (ZVRA) director files report showing no holdings - Stock Titan
Schroder Investment Management Group Acquires New Position in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Zevra Therapeutics, Inc. $ZVRA Holdings Boosted by Stonepine Capital Management LLC - MarketBeat
Zevra Therapeutics Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
How Zevra Therapeutics Inc. stock performs after earningsPortfolio Value Report & Expert Approved Momentum Ideas - Newser
Behavioral Patterns of ZVRA and Institutional Flows - Stock Traders Daily
Does Zevra Therapeutics’ (ZVRA) Board Turnover Subtly Recast Its Leadership and Capital Allocation Narrative? - simplywall.st
Why Zevra Therapeutics Inc. stock is favored by top institutionsDollar Strength & Stepwise Entry and Exit Trade Signals - Newser
Legal & General Group Plc Grows Stock Position in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Zevra Therapeutics (ZVRA): Evaluating Valuation Following High-Profile Board Appointment and CFO Transition - simplywall.st
Zevra Therapeutics, Inc. Announces Director and Committee Changes, Effective as of December 2, 2025 - marketscreener.com
Zevra Therapeutics appoints Alicia Secor to board of directors; announces retirement of Wendy Dixon - marketscreener.com
Zevra Therapeutics Appoints Alicia Secor to Board - TipRanks
ZVRA FinancialsIncome Statement - Quiver Quantitative
Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD - The Manila Times
Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors, Announces Retirement of Wendy Dixon - Quiver Quantitative
Zevra Therapeutics Announces Board Changes - TradingView — Track All Markets
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):